Experimental vaccine takes on deadly childhood brain tumors
NCT ID NCT04808245
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 1 trial tests a peptide vaccine designed to target a specific mutation (H3K27M) found in certain aggressive brain tumors called diffuse midline gliomas. Fifteen newly diagnosed patients receive the vaccine along with the immunotherapy drug atezolizumab after standard radiotherapy. The main goals are to check safety and see if the vaccine triggers an immune response against the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- H3K27M peptide vaccine and atezolizumab (Tecentriq)
- What this could lead to
- If successful, this could point toward a new treatment option for a rare and aggressive brain cancer by training the immune system to attack tumor cells.
- What could go wrong
- This is a very early phase 1 trial with only 15 participants, so safety and immune response are the main goals—not yet proof of effectiveness. The treatment may not shrink tumors or extend survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinic and Polyclinic for Neurosurgery, University Hospital Carl Gustav Carus Dresden
Dresden, Saxony, 1307, Germany
-
Clinical Neuro-Oncology Section, University Hospital Bonn (UKB)
Bonn, North Rhine-Westphalia, 53127, Germany
-
Department of Neurology and Polyclinic, Universitiy Clinic Heidelberg
Heidelberg, Baden-Wurttemberg, 69120, Germany
-
Department of Neurosurgery with Pediatric Neurosurgery
Berlin, State of Berlin, 10117, Germany
-
Dr. Senckenberg Institute for Neurooncology, University Hospital Frankfurt
Frankfurt am Main, Hesse, 60528, Germany
-
Neurooncology Department, University Hospital Essen
Essen, North Rhine-Westphalia, 45147, Germany
-
University Clinic Tuebingen, Neurological Clinic, Department of Neurology
Tübingen, Baden-Wurttemberg, 72076, Germany
-
University Medical Center Mannheim, Department of Neurology
Mannheim, Baden-Wurttemberg, 68167, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.